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The deposition of amyloid-beta (Ab) aggregates in the brain is a major pathological hallmark of Alzheimer’s
disease (AD). Ab is generated from the cleavage of C-terminal fragments of the amyloid precursor protein
(APP-CTFs) by g-secretase, an intramembrane-cleaving protease with multiple substrates, including the
Notch receptors. Endogenous modulation of g-secretase is pointed to be implicated in the sporadic, age-
dependent form of AD. Moreover, specifically modulating Abproduction has become a priority for the safe treat-
ment of AD because the inhibition of g-secretase results in adverse effects that are related to impaired Notch
cleavage. Here, we report the identification of the adipocyte differentiation protein APMAP as a novel endogen-
ous suppressor of Ab generation. We found that APMAP interacts physically with g-secretase and its substrate
APP. In cells, the partial depletion of APMAP drastically increased the levels of APP-CTFs, as well as uniquely
affecting their stability, with the consequence being increased secretion of Ab. In wild-type and APP/ presenilin
1 transgenic mice, partial adeno-associated virus-mediated APMAP knockdown in the hippocampus increased
Ab production by∼20 and∼55%, respectively. Together, our data demonstrate that APMAP is a negative regu-
lator of Abproduction through its interaction with APP andg-secretase. All observed APMAP phenotypes can be
explained by an impaired degradation of APP-CTFs, likely caused by an altered substrate transport capacity to
the lysosomal/autophagic system.
INTRODUCTION
In the neurodegenerative amyloid cascade of Alzheimer’s
disease (AD), quantitative and qualitative changes in the produc-
tion of amyloid-beta (Ab) peptides and their aggregation into
senile plaques precede the formation of neurofibrillary tangles
and initiate the pathological process causing the disease (1,2).
Neurotoxic Ab peptides are generated by successive cleavages
of the amyloid precursor protein (APP) by b- and g-secretases.
APP is first processed by the b-secretase BACE1, leading to
the formation of a 99-amino-acid long APP C-terminal fragment
(APP-C99 or APP-CTFb). The cleavage of APP-CTFb by
g-secretase liberates Ab peptides that are 38–43 amino acids
in length, with Ab42 being a major component of the senile
plaques (3). Yet, APP is mainly cleaved within the Ab region
by thea-secretases ADAM10/17 to release APP-CTFa, the pro-
cessing of which byg-secretase results in N-terminally truncated
and non-toxic Ab peptides. g-Secretase is a ubiquitously
expressed membrane protease complex that processes a long
list of type I transmembrane proteins, including APP, the
Notch-1 receptor and several synaptic cell adhesion molecules
(4–6). Active g-secretase is comprised of five protein compo-
nents: Nicastrin (NCT), Presenilin N- and C-terminal fragments
(PS-NTF and PS-CTF), Aph1 and Pen-2 (7). Because they
prevent the production of Ab peptides, g-secretase inhibitors
(GSI) have been extensively investigated in the clinic for the
treatment of AD. However, recent human GSI trials revealed sig-
nificant side effects linked to impaired Notch cleavage (8).
Therefore, specifically modulating g-secretase and Ab produc-
tion, without interfering with other physiological processes, is
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an attractive strategy to safely treat AD (9). Because endogenous
g-secretase modulating factors are potential therapeutic targets,
but also possibly implicated in the sporadic forms of AD, we
aimed to identify new g-secretase-interacting proteins (GSPs)
that are capable of modulating Ab production.
RESULTS
Identification of GSPs modulating Ab production
Highly purified and active g-secretase prepared from Chinese
hamster ovary (CHO) cells overexpressing the four subunits of
the protease complex (10) was resolved by blue-native gel
electrophoresis (Fig. 1A), and the band corresponding to the
complex was excised for protein content analysis by LC-MS/
MS mass spectrometry. This approach led to the identification
of seven GSPs encoded by the genes ATP1a1, RTN4, VAMP2,
VAMP3, TSPAN6, APMAP and HSPA5 (Fig. 1A; peptides
identified by LC-MS/MS are listed in Supplementary Material,
Fig. S1). As expected from a g-secretase overexpression
system, the silver-stained SDS–PAGE of the protease prepar-
ation used for the native gel (Fig. 1A) confirmed the trace
amounts of GSPs relative to the predominant g-secretase subu-
nits (Supplementary Material, Fig. S2). Because ATP1a1,
VAMP2/3 and HSPA5 had previously been reported to interact
physically with either g-secretase or APP (11,12), we focused in
our study on RTN4, APMAP and TSPAN6. RTN4 encodes for
the myelin-associated multi-pass membrane protein reticulon-4
(Nogo), a neurite outgrowth inhibitor limiting plasticity in the
healthy adult brain and neuronal regeneration during brain
injury (reviewed in13). APMAP encodes for a 415-amino-acid
long single-pass type-II glycosylated membrane protein that is
implicated in the regulation of white adipose tissue differenti-
ation (14,15). TSPAN6 belongs to the tetraspanin superfamily
of multi-pass membrane proteins interacting with multiple
immune-related molecules, including immune receptors, integ-
rins, signaling molecules and functioning as important immune
response modulators (16). The neurobiological functions of
APMAP and TSPAN6 remain unknown.
First, the expression of the RTN4, APMAP and TSPAN6
genes was reduced by small-interfering RNA (siRNA) in HeLa
cells as well as in HEK cells overexpressing APP harboring
the Swedish double mutation near the b-secretase cleavage
site (mutation resulting in increased total Ab levels; HEK-
APPSwe). In HeLa and HEK-APPSwe cells, depletion by
60% of TSPAN6 lowered APP-CTFs levels by 38 and 40%,
respectively (Fig. 1B and C). In contrast, depletion of RTN4
and APMAP (both by 75%) caused a strong accumulation of
APP-CTFs, respectively, by 181 and 286% in HeLa cells and
by 25 and 52% in HEK-APPSwe cells (Fig. 1B and C and Sup-
plementary Material, Fig. S3). This siRNA knockdown of indi-
vidual genes did not interfere with the maturation or protein
levels of a-, b- or g-secretases, with the exception of increased
ADAM10 associated with reduced RTN4 (Supplementary
Material, Fig. S4). Importantly, Ab secreted from HEK-
APPSwe cells depleted for the expression of TSPAN6, RTN4
and APMAP directly reflected the levels of intracellular APP-
CTFs (Fig. 1D). Indeed, siRNAs targeting TSPAN6 reduced
the levels of Ab40 by 25 + 7.5%, while siRNAs targeting
RTN4, and APMAP raised Ab40 levels by 52 + 1.8 and
60 + 10.1%, respectively (Fig. 1D). Yet, full-length APP
(APP-FL) protein levels remained unchanged in the APMAP
knockdown experiments (Fig. 1B and C and Supplementary
Material, Fig. S3). In contrast, depletion of RTN4 in both
HeLa and HEK-APPSwe cells, respectively, caused 170 and
140% increases in APP-FL levels (Fig. 1B and C).
Figure 1. Identification of endogenous modulators of g-secretase and Ab pro-
duction. (A) Analysis by LC-MS/MS of the protein components of the highly
purified g-secretase complex. (B and C) siRNA knockdown of TSPAN6,
RTN4 and APMAP affects APP-CTFs in HeLa cells (B) and HEK cells overex-
pressing APP bearing the Swedish mutation that causes early-onset familial Alz-
heimer’s disease (HEK-APPSwe; C). Biological duplicates are shown for each
siRNA condition. (D) Correlation between APP-CTFs levels and Ab40 produc-
tion in HEK-APPSwe cells with reduced TSPAN6, RTN4 and APMAP expres-
sion. APP-CTFs levels were estimated by densitometric analysis, while Ab40
levels were quantified by ELISA. Student’s t-test was applied for statistical
analysis; significance is shown as mean + SD, ∗P, 0.05; ∗∗P , 0.01; Ab40:
n ¼ 6/group; APP-CTFs: n ¼ 4/Scramble, TSPAN6and APMAP groups;
n ¼ 3/RTN4 group. b-Actin served as a protein loading control. mAPP-FL and
iAPP-FL: mature and immature APP full-length.
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Genetic inhibition of APMAP increases Ab production
We further focused on the adipocyte plasma membrane-
associated protein APMAP because (i) its knockdown displayed
the biggest variations in APP-CTFs and Ab40 (Fig. 1B–D), (ii)
its knockdown was associated with a unique effect on the stabil-
ity against proteolytic degradation of APP-CTFs (see below and
Fig. 3), and (iii) its brain functions remain unknown. First, we
confirmed by ELISA and a high-resolution Tris-Tricine urea
gel that reduced APMAP expression in HEK-APPSwe cells
increased the secretion of full-length total Ab (Ab1-x),
Ab1-40 and Ab1-42 in a dose-dependent manner (Supplemen-
tary Material, Fig. S5), without affecting the levels or the matur-
ation of the secretases (Supplementary Material, Fig. S6). Mass
spectrometric analysis of secreted Ab revealed no changes in the
Ab profile (Supplementary Material, Fig. S5), suggesting that
APMAP does not affect the sequential and specific processing
of APP by g-secretase. Moreover, APMAP1 purified from
E. coli or CHO cells did not interfere with the processing of
APP-CTFb in our cell-free g-secretase activity assays, arguing
against a direct effect of APMAP on the activity of the mature
g-secretase (Supplementary Material, Figs S7 and S8). Finally,
purified APMAP1 did not prove to be a substrate for g-secretase
(Supplementary Material, Figs S7 and S8). The latter observa-
tion excludes an APP phenotype (accumulation of APP-CTFs)
caused by substrate competition, after siRNA-dependent deple-
tion of APMAP1.
APMAP is expressed in neurons and interacts physically
with g-secretase and APP
Next, the physical interaction between APMAP1 and the
g-secretase complex and APP was confirmed in both HEK-
APPSwe and CHO cells overexpressing APMAP1-Flag or an
untagged control APMAP1 (Fig. 2 and Supplementary Material,
Fig. S9). In these experiments, all subunits of the g-secretase
complex, as well as APP-FL and APP-CTFs, specifically and
sequentially co-sedimented and co-precipitated with APMAP1-
Flag (Fig. 2A). In sharp contrast, these proteins did not co-
precipitate with the untagged control APMAP1 (Fig. 2A).
Under our experimental conditions, other APP processing
enzymes including BACE1 or ADAM10 did not bind to
APMAP (Fig. 2A). Next, by combining immunohistochemistry
and confocal imaging, we also found that APMAP1 is highly
expressed in mouse primary cortical neurons where it adopts
an axonal and somatodendritic distribution (Fig. 2B and Supple-
mentary Material, Fig. S10). Our results further show that
APMAP partially co-localizes with Nicastrin, a subunit of the
g-secretase complex, mainly in the neuronal cell body (Fig. 2B
and Supplementary Material, Fig. S10). Consistent with the pre-
dicted topology of APMAP (type-II transmembrane protein),
our data suggest that APMAP1 traffics via the secretory
pathway to the plasma membrane and adopts a somatodendritic
cellular distribution. We further found that APMAP co-localizes
partially with APP-FL/APP-CTFs, both in cytosolic and neuritic
cellular compartments (Fig. 2B and Supplementary Material,
Fig. S10). Altogether, these data support the existence of neuron-
al high molecular weight complexes made of APMAP and
g-secretase, APMAP and APP-FL/CTFs, and possibly all three
components.
APMAP controls the levels and stability of APP C-terminal
fragments
Further supporting an association with APP, we found that
partial depletion of APMAP in HeLa cells altered the profile of
endogenous APP-CTFs. As observed on a high-resolution Tris-
Tricine urea gel, APMAP siRNA combined with low concentra-
tions of the GSI DAPT led to the generation of three distinct
forms of APP-CTFa (CTFa1, a2 and a3), with two forms
migrating with apparent sizes of 8.5 and 8.0 kDa, instead of
9.0 kDa (Fig. 3A). The mass spectrometric characterization of
APP-CTFa1-3 (APP-C80, C74 and C71; Fig. 3B and C and Sup-
plementary Material, Fig. S11) further suggested that endogen-
ous APP-CTFs undergo either partial degradation by yet
unknown proteases or further proteolytic processing [possibly
by BACE2 (17)], supporting a possible APP stabilization func-
tion for APMAP.
APMAP modulates Ab production in WT and Alzheimer’s
mice
Next, and to determine whether our findings are relevant in vivo,
we induced the partial knockdown of APMAP in wild-type mice
and transgenic APP/ presenilin 1 (PS1) Alzheimer’s mice. Five
week-old mice (males and females) were bilaterally injected in
the dorsal hippocampus with serotype 9 adeno-associated viral
vectors (AAV9) encoding shRNAs targeting APMAP (Fig. 4A
and C and Supplementary Material, Figs S12 and S13). As
recently demonstrated by Aschauer et al. (18), AAV9 vectors,
when injected in the hippocampus, have a generally broad
tropism for many different brain cell types, including oligoden-
drocytes, microglia, astrocytes and neurons (including inhibi-
tory neurons). In our study, four weeks post-hippocampus
injection, the global expression of APMAP was reduced by
50% in male WT mice (Fig. 4B) and by 35% in male APP/
PS1 mice (Fig. 4D), whereas Ab production was increased by
20% in male WT mice (Fig. 4B) and by 55% in male APP/
PS1 mice (Fig. 4D). Interestingly, under our experimental condi-
tions, no significant effect on Abproduction was found in female
mice (Supplementary Material, Fig. S13), which may be linked
to the weaker APMAP knockdown observed in these animals
(APMAP knockdown by 35% in female WT mice and by
25% in female APP/PS1 mice). Finally, APMAP depletion
in the brain of WT and AD mice does not seem to affect
APP-CTF levels (Fig. 4B and D), in contrast to HeLa and
HEK-APPSwe cells (Fig. 1B and C). This apparent discrepancy
may result from the weaker APMAP knockdown in mice (by
35–50%), when compared with that observed in HeLa and
HEK-APPSwe cells (by 75%). In support of this explanation,
the dose-dependent reduction of APMAP in HEK-APPSwe cells
revealed a critical step for APMAP depletion (50% depletion,
0.2 nM APMAP siRNA), above which small changes in APMAP
expression are associated with big changes in APP-CTFs accu-
mulation (Supplementary Material, Fig. S14).
APMAP modulates APP-CTFs through the lysosomal
pathway
Finally, we investigated whether the main APMAP phenotype,
namely co-increases of both APP-CTFs and Ab after APMAP
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Figure 2. APMAP interacts physically and co-localizes with g-secretase, APP-FL and APP-CTFs. (A) Velocity co-sedimentation and co-immunoprecipitation of
APMAP with the g-secretase complex, APP-FL and APP-CTFs. Total membrane protein extracts from HEK-APPSwe cells transiently overexpressing
hAPMAP1 or hAPMAP1-Flag were sedimented on an 18–28% glycerol gradient containing 0.1% CHAPSO. Each fraction was collected and analyzed by
western blot for APMAP1, APP-FL, APP-CTFs and mature and immature g-secretase (top panels). Next, proteins interacting with hAPMAP1-Flag (Flag) were
affinity-precipitated in the fractions labeled in red with M2 anti-Flag affinity resin (lower panel). Untagged APMAP (hAPMAP1, also labeled ‘-’ in the figure)
served as a control for the specific co-precipitation. (B) Immunohistochemical co-localization of APMAP (green) with the g-secretase subunit Nicastrin (red,
upper panel) or APP (red, lower panel) in 14 days in vitromouse primary cortical neurons. Scale bar: 10 mm. Both confocal images (left panels) and Z-stack projections
(right panels) are shown with a microscope objective magnification of 40×. For comparison, un-merged images for APMAP, NCT, APP-CTFs and DAPI are shown in
Supplementary Material, Fig. S10. mNCT and iNCT, mature and immature Nicastrin.
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knockdown, could be explained by an impaired degradation of
APP-CTFs through the lysosomal–autophagic pathway. To do
so, a pharmacological approach was used, by taking advantage
of Chloroquine, a well-known inhibitor of the lysosomal–autop-
hagic pathway. Chloroquine is a lysosomotropic agent that
impedes the lysosomal pathway by inhibition of lysosomal
enzymes and lysosomal protein degradation, and by preventing
the fusion of endosomes and lysosomes (19). Chloroquine,
because it raises the lysosomal pH, also inhibits autophagy
(20). To test whether APMAP can regulate the levels of
APP-CTFs through the lysosomal pathway, HEK-APPSwe
and HeLa cells were incubated for 12 h with, respectively, 25
and 50 mM Chloroquine, in the presence of APMAP or after
APMAP depletion. As shown in Fig. 5A and B, Chloroquine
treatments in the presence of APMAP (scramble siRNA) were
associated with a 2.1-fold increase of APP-CTFs in
HEK-APPSwe cells and a 3.4-fold increase of the same proteins
in HeLa cells, when compared with DMSO-treated controls.
This observation clearly supports a lysosomal degradation of
the APP-CTFs in these two cell types. Interestingly, APMAP
depletion strongly reinforced the Chloroquine-dependent accu-
mulation of APP-CTFs. The densitometric analysis of the
western blots indeed revealed additional 2.2-fold and 1.6-fold
increases of APP-CTFs in HEK-APPSwe and HeLa cells
co-treated with Chloroquine and the APMAP siRNA, when
compared with cells co-treated with Chloroquine and the
scramble siRNA. The latter observation is consistent with a
Chloroquine- and APMAP-dependent synergistic effect pos-
sibly caused by reduced lysosomal degradation and reduced
lysosomal transport of APP-CTFs.
Altogether, our data suggest that APMAP modulates the
levels of APP-CTFs through the lysosomal–autophagic system.
DISCUSSION
In this study, we analyzed the protein composition of highly puri-
fied and active g-secretase complexes and identified seven pro-
teins that interact physically with the enzymatic complex.
Among these proteins, TSPAN6 was found to positively regulate
Figure 3. APMAP controls the levels and the stability of APP-CTFs. (A) siRNA knockdown of APMAP in HeLa cells quantitatively and qualitatively impacts
APP-CTFs. Reduced APMAP expression correlates with increased APP-CTFs and the formation of three forms of APP-CTFa (CTFa1, a2 and a3), as revealed
on a Tris-Tricine urea gel (left panel). This phenotype is further amplified in the presence of 1 mM GSI DAPT (right panel). Biological triplicates are shown. (B)
MALDI-TOF mass spectrometric analysis of APP-CTFa1, a2 and a3 immunoprecipitated from DAPT-treated cells with siRNA-reduced APMAP expression.
(C) Peptide sequences of N-terminal truncated APP-CTFa1 (C80), -CTFa2 (C74) and -CTFa3 (C71).
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the processing of APP and the production of Ab, consistent with
previous work on tetraspanins TSPAN12, TSPAN28 and
TSPAN29 (12,21). Another of our proteins identified to be asso-
ciated with the g-secretase complex is RTN4, which has been
shown previously to negatively regulate Ab production by inter-
acting with the b-secretase BACE1 (22). We confirmed this
effect, as reduced RTN4 led to increased Ab production
(Fig. 1D) and suggest for the first time that the Ab-suppressing
function of RTN4 may also be based on a physical interaction
with the g-secretase complex.
Importantly, we further identified the adipocyte differenti-
ation protein APMAP (15) as an endogenous inhibitor of Abpro-
duction that binds to both APP and g-secretase, and controls the
levels and the stability of APP-CTFs. Additionally, APMAP
does not affect the processing of other g-secretase substrates,
including the Notch receptor, and the neuronal cell adhesion
molecules Neurexin-3b and Neuroligin-1 (Supplementary Ma-
terial, Fig. S15). Consistent with the Allen Brain and Human
Protein Atlases (Supplementary Material, Fig. S16), we further
showed that APMAP is expressed in the brain, and more specif-
ically in neurons where it co-localizes at least partially with APP
and g-secretase (Fig. 2B). In mice, APMAP knockdown in both
neuronal and glial cells (18; Fig. 4A and C) increased Ab levels
in the hippocampus 4 weeks after injection of the AAV9 with
shRNAs targeting APMAP (Fig. 4). Yet, a decade of research
on which forms and structures of Ab impair neuronal functions
has concluded that (i) small and diffusible assemblies of mis-
folded and self-aggregating Ab peptides are probably the princi-
pal cytotoxic forms, but also that (ii) insoluble amyloid fibrils
and the amyloid plaques cause neuritic alterations including a
Figure 4. APMAP modulates Ab production in vivo. Five-week-old wild-type (A and B) or APP/PS1 transgenic (C and D) male mice were injected in the dorsal
hippocampus with AAV9 expressing APMAP shRNA or a scrambled control shRNA, together with a GFP reporter. Four weeks post-injection, AAV9 transduction
is highly efficient and is mainly restricted to the hippocampus (A and C). Wild-type (B) or APP/PS1 (D) males displayed significant 50% and 35% decreases of
APMAP expression (mean + SD; ∗∗∗P, 0.001;n ¼ 6/group), associated with significant20 and55% increases in total Ab levels in the hippocampus (∗P, 0.05;
∗∗P, 0.01; n ¼ 6/group). Student’s t-test was applied for the statistical analysis. b-Actin served as a protein loading control. (A and C) Scale bar: 500 mm.
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decreased efficiency of neurotransmission (reviewed in 23).
Whether APMAP preferentially affects the production of
soluble Ab assemblies or the deposition of Ab plaques
remains unknown and will require specific and long-term inves-
tigations in AD transgenic mice.
At the molecular level, APP is cleaved into sAPP-a and
CTF-a by a-secretase or cleaved into sAPP-b and CTF-b by
b-secretase. Then, g-secretase cleaves CTF-a into secreted
24–26 residues long P3 peptides and cytoplasmic APP-
intracellular domain (AICD), and cleaves CTF-b into 38–43
residues long Ab peptides and AICD. Under physiological con-
ditions, APP processing by g-secretase is associated with
increased Ab production and reduced CTFb levels. In contrast,
if a molecule inhibits g-secretase, reduced Ab production is
associated with increased CTFb levels. In our study, depletion
of APMAP led to both increases of Ab and CTFs (Figs 1 and
3). Moreover, depletion of APMAP did not affect the levels of
sAPP-a or sAPP-b (Supplementary Material Figs 4 and 6), or
the expression of APP-FL (Figs 1 and 3), suggesting that (i) a-
andb-secretases are not targets for APMAP, and (ii) both cleav-
age and production of APP-FL are not affected by APMAP. All
observed phenotypes including the co-increases of APP-CTFs
and Ab after APMAP knockdown could be explained by an
impaired degradation of APP-CTFs (depicted in Fig. 6). This hy-
pothesis is supported by the observation that APMAP depletion
caused an increased accumulation of APP-CTFs in cells treated
with Chloroquine, a well-known inhibitor of the lysosomal–
autophagic pathway (Fig. 5).
In the molecular hypothesis proposed in Figure 6, APMAP, by
interacting physically with APP-CTFs (Fig. 2), would promote
the transport of these substrates from the endosomes to the lyso-
somes, with the consequence being their degradation, thus redu-
cing both APP-CTFs and Ab levels. Indeed, it has been
previously reported that APP-CTFs can be delivered to the lyso-
somes by two pathways: the endosomal–lysosomal pathway
(heterophagy) and the authopagic pathway, causing the degrad-
ation of the Ab precursor proteins (24–26). Similar to the phe-
notypes observed in our study with reduced APMAP, genetic
or pharmacological inhibition of the lysosomal–autophagic
system led to the significant intracellular accumulation of
APP-CTFs and increased Ab secretion (27,28). Thus, APMAP
depletion would lead to impaired degradation, with the conse-
quence being both increases of APP-CTFs and Ab. Moreover,
impaired APP-CTFs degradation would make these g-secretase
substrates accessible to yet unidentified proteases and trigger
their proteolysis (Fig. 3). Alternatively, and still by interacting
physically with APP-CTFs, APMAP could also transport these
substrates to the g-secretase complex, explaining the possible
physical interaction between APMAP, APP-CTFs and the
enzyme (Fig. 2). Since abnormalities in the neuronal lyso-
somal–autophagic system have been associated with the path-
ology of AD (reviewed in 29), understanding the precise
Figure 5. APMAP regulates cellular APP-CTFs levels through the lysosomal–autophagic pathway. HEK-APPSwe (A) and HeLa (B) cells treated either with a
scrambled control siRNA or with APMAP siRNA were incubated for 12 h with the lysosomal inhibitor Chloroquine (25 and 50 mM, respectively). Total membrane
protein extracts were prepared and analyzed by western blot for APMAP1, APP-FL and APP-CTFs (left panels). Biological duplicates are shown andb-actin served as
a protein loading control. Next, APP-CTFs bands were quantified by densitometry (right panels) and Student’s t-test was applied for statistical analysis with n ¼ 4/
group. ∗∗P , 0.01; ∗∗∗P , 0.001.
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molecular mechanisms by which APMAP can regulate APP-CTFs
degradation deserves further investigation.
Yet, APP-CTFs do not seem to only be degraded through the
lysosomal–autophagic system. Indeed, Bustamante et al. (30)
have recently demonstrated in human H4 neuroglioma cells
that APP-C99 is actively degraded in the endoplasmic reticulum
in an ubiquitin and proteasome-dependent manner. Whether
APMAP can play an active role in the proteasome-dependent
degradation of APP-CTFs (including a crosstalk between the
lysosomal and proteasomal systems) also requires further
investigation.
APMAP also controls adipogenesis and consequently the
adipocytic release of potential g-secretase modulators, includ-
ing leptin (31,32) and cholesterol (33–35). Moreover, the
Figure 6.Molecular hypothesis for the regulation of APP-CTFs/Ab levels by APMAP. In this hypothesis, APMAP is implicated in the transport of APP-CTFs to the
lysosomal–autophagic system, where it undergoes substrate degradation. Consistent with the observed cellular phenotypes (Figs 1 and 3), depletion of APMAP would
impair this transport capacity and consequently trigger increased APP-CTFs levels, which in turn cause increased Ab production. Impaired degradation would further
make APP-CTFs substrates accessible to yet unidentified proteases, explaining the N-terminal truncated species observed in cells with depleted APMAP (Fig. 3).
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expression of APMAP is regulated by the peroxisome prolifer-
ation-activated receptor PPARg (14,15), which has also been
shown to decrease Ab production (36). In return, the processing
of Notch by g-secretase inhibits PPARg and adipocyte differen-
tiation (37). Thus, reducing Ab production by interfering with
the PPARg/APMAP/g-secretase regulatory loop could poten-
tially represent a therapeutic approach to slow down the path-
ology of AD. Moreover, APMAP, by participating in the gut/
adipose tissue/brain crosstalk and regulating cerebral Ab
levels, could possibly provide new molecular insight into the
statistical link between AD and obesity or diabetes.
MATERIALS AND METHODS
g-Secretase purification, tryptic digestion and mass
spectrometry
The g-secretase complex was purified as previously described
(10) and was run on a NativePAGE Novexw Bis–Tris 4–16%
gel for BN-PAGE analysis (Invitrogen, Carlsbad, CA, USA).
Next, the complex was visualized by Coomassie staining,
excised and cut into small pieces. Proteins were reduced, alky-
lated and subjected to in-gel digestion with trypsin. Briefly, gel
pieces were destained, desiccated by incubating twice in
200 ml of 50 mM ammonium bicarbonate and 50% ethanol for
20 min and dried with a vacuum concentrator. The samples
were then incubated overnight at 378C with trypsin (12.5 ng/ml).
For liquid chromatography coupled to tandem mass spectro-
metry (LC-MS/MS) analysis after extraction from gel slices,
peptides were resuspended in 2% Acetonitril/0.1% Formic
Acid and separated by reverse-phase chromatography on a
Dionex Ultimate 3000 RSLC nanoUPLC system connected
in-line with an Orbitrap Elite (Thermo Fischer Scientific,
Waltham, MA, USA). The instrument was operated in an
information-dependent mode where peptide masses were
selected for collision-induced dissociation to generate tandem
mass spectra. A database search was performed using Mascot
2.3 (Matrix Science, Boston, MA, USA) and SEQUEST in
Proteome Discoverer v.1.3 against a human database (UniProt
release 2013_01; 87613 sequences) and Mammalian database
(UniProt release 2011_07; 91104 sequences). All searches
were performed with trypsin cleavage specificity, with up to
three missed cleavages allowed, an ion mass tolerance of
10 ppm for the precursor and 0.5 Da for the fragments. Carbami-
domethylation was set as a fixed modification, whereas oxida-
tion (M), acetylation (protein N-term) and phosphorylation
(STY) were considered variable modifications. Data were
further processed and inspected using Scaffold 3 software
(Proteome Software).
Cell lines, cell cultures and treatments with siRNA or GSI
Human embryonic kidney cells (HEK 293T), human cervical
carcinoma cells (HeLa) and CHO cells were routinely grown
in DMEM with 10% fetal bovine serum and penicillin/strepto-
mycin in a humidified 5% CO2 atmosphere. The CHO cells
stably expressing Flag-tagged APMAP and the HEK cells
stably expressing APP with the Swedish mutation [HEK-
APPSwe (38)] were maintained in DMEM with 10% FBS sup-
plemented with 150 mg/ml Geneticin G418 (Gibco, Thermo
Fischer Scientific). HEK cells stably expressing the g-secretase
substrate NotchDE [HEK-N7 (39)] were cultured in DMEM with
10% FBS supplemented with 250 mg/ml Zeocin (Gibco). For
siRNA knockdown experiments, cells were treated for 3 days
with allstar negative control siRNA (Qiagen, Germantown,
MD, USA), APMAP (5′-TTCACCGATTCTAGCAGCAA
A-3′, Qiagen), RTN4 (5′-CAGGGCATATCTGGAATCTGA-
3′, Qiagen) or Tspan6 (5′-CTCTCGTGCCATAACAAATAA-3′,
Qiagen) siRNA duplexes complexed with Lipofectamine
RNAiMax from Invitrogen. For Ab peptides secreted in the con-
ditioned medium of HEK-APPSwe cells, Ab1-X (IBL), Ab1-40
(Invitrogen) and Ab1-42 (Invitrogen) were quantitatively mea-
sured by ELISA, according to the protocol provided by the
manufacturer. For inhibition of cellular g-secretase activity,
cells were incubated for 4 h with 10 mM of the g-secretase-
specific inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-
phenylglycine t-butyl ester (DAPT; Sigma-Aldrich, GmbH,
Buchs, Switzerland). For inhibition of the lysosomal pathway,
HEK-APPSwe and HeLa cells were incubated for 12 h with 25
and 50 mM of Chloroquine (Sigma-Aldrich), respectively.
Western blotting and antibodies
Whole cell extracts were prepared in 50 mM HEPES buffer con-
taining 1% NP40 and complete protease inhibitor cocktail
(Roche Applied Sciences, Basel, Switzerland) and were sepa-
rated by electrophoresis on homemade 12% acrylamide Tris-
glycine SDS–PAGE or NuPAGE Novexw 4–12% Bis–Tris
gels (Invitrogen) for SDS–PAGE analysis of APMAP purifica-
tion and g-secretase activity. High separation of APP-CTFs or
Ab peptides was resolved using 15% acrylamide and 6 M urea
Tris-Tricine SDS–PAGE as described previously (40) or by a
Tris-bicine-urea gel (41), respectively. Proteins were transferred
onto nitrocellulose membranes and probed with antibodies
against APP-FL and APP-CTFs (CT15, Sigma-Aldrich, Saint
Louis, MS, USA), as well as sAPPa (6E10; Covance, Berkeley,
CA, USA) and total sAPP (22C11; Millipore, Billerica, MA,
USA), NCT (N1660 or NCT164, BD Bio-Sciences, Bedford,
MA, USA), PS1-NTF (MAB1563, Chemicon International,
Temecula, CA, USA), PS1-CTF (MAB5232, Chemicon Inter-
national), Aph1 (O2C2, Covance), Pen-2 (UD1, a gift from
Helena Karlstro¨m, KI Stockholm, Sweden), ADAM10 (Prosci,
Poway, CA, USA), BACE1 (EE17, Sigma-Aldrich), APMAP
(4F6, AbCam, Cambridge, UK), RTN4 (Ab2, Sigma-Aldrich),
Tspan6 (AbCam), Notch-ICD (Val1744, Cell Signaling,
Boston, MA, USA) or b-actin (Sigma-Aldrich). Anti-mouse,
rabbit and rat IgGs conjugated to Alexa 680 were purchased
from Invitrogen, and the Odyssey infrared imaging system
(LICOR, Lincoln, NE, USA) was used to detect the fluorescent
signal.
Glycerol gradient velocity sedimentation and
co-immunoprecipitation
Membranes were prepared by osmotic shock from HEK-
APPSwe cells transiently expressing either Flag-tagged or
untagged human APMAP1, as previously described (4). Next,
membrane proteins solubilized in 1% CHAPSO were loaded
onto an 18–28% glycerol gradient containing 11 × 950 ml frac-
tions prepared in 0.1% CHAPSO. After centrifugation for 15 h at
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220 000g, 950 ml fractions were collected and analyzed by
western blotting. For co-immunoprecipitation experiments, all
fractions collected after glycerol velocity sedimentation were
diluted twice with 0.2% digitonin in Tris-buffered saline
(TBS) and incubated with 50 ml of M2 resin (Sigma-Aldrich)
at 48C overnight. The beads were then washed three times for
15 min in TBS with 0.1% digitonin and collected in 50 ml of
diluted (1:2 in water) Laemmli sample buffer.
Immunostaining
Mouse primary cortical neurons were prepared from embryonic
day 17 Of1 fetal mouse brains. Cortices were digested in medium
containing papain (20 U/ml, Sigma-Aldrich) and dissociated by
mechanical trituration. Cells were plated in the neurobasal
medium (Invitrogen) supplemented with B27 (Invitrogen) and
2 mM Glutamax (Life Technologies, Thermo Fischer Scientific)
on poly-L-ornithine (Sigma-Aldrich)-coated plates at 378C in a
humidified 5% CO2 atmosphere. At in vitro day 14, neurons
were fixed with 4% paraformaldehyde and permeabilized in
phosphate buffered saline (PBS) containing 0.1% Triton
X-100 for 10 min. The cells were then incubated in citrate
buffer (10 mM sodium citrate, 0.05% Tween-20, pH 8.0) for
30 min at 95–1008C. After cooling at room temperature, non-
specific antibody binding was prevented by incubation in
0.25% cold water fish gelatin (Sigma-Aldrich) diluted in PBS
for 45 min. Following the blocking step, the cells were incubated
with antibodies against APMAP (GTX46051, Gentex, Irvine,
CA, USA), APP-CTFs (4G8, AbCam Cambridge, UK) or Nicas-
trin (NCT164, BD Bio-Sciences, Franklin Lakes, NJ, USA).
Finally, the fixed cells were incubated with anti-rabbit Alexa
488 and anti-mouse Alexa 568 (Invitrogen) secondary anti-
bodies. Image acquisition was performed with a Zeiss
LSM700 UP2 microscope using a 40× objective.
Immunoprecipitation-mass spectrometry (IP-MS) analysis
of Ab and APP-CTFs
Ab secreted from HEK-APPSwe cells treated with scrambled or
APMAP siRNAs were immunoprecipitated overnight using the
monoclonal anti-Ab antibody 4G8 (AbCam) and protein
G-coupled agarose (Roche Applied Sciences). Ab was eluted
using a 1:20:20 (vol:vol:vol) mix of 0.1% (vol/vol) trifluoroace-
tic with acid:acetonitrile:H20 mixed 1:1 (vol:vol) with saturated
CHCA (a-cyano-4-hydroxycinnamic acid) and analyzed by
MALDI-TOF mass spectrometry in the reflectron mode on an
ABI 4800 MALDI-TOF/TOF mass spectrometer (Applied Bio-
systems, Thermo Fischer Scientific). Intracellular APP-CTFs
from whole protein extracts prepared from cells treated with
APMAP siRNA and/or DAPT were immunoprecipitated with
an antibody targeting the CTF portion of APP (CTF15; Sigma-
Aldrich GmbH, Buchs, Switzerland). Next, APP-CTFs were
washed two times in 1% NP40-HEPES and two more times
in deionized water, and then eluted in 0.1% (vol/vol)
trifluoroacetic acid with acetonitrile:H20 mixed 1:1 (vol:vol),
dried with a vacuum pump and finally resolubilized in the
same elution buffer saturated with sinapinic acid (3–4-
hydroxy-3,5-dimethoxyphenyl prop-2-enoic acid). All spectra
were acquired in the linear mode with an ABI 4800 MALDI-
TOF/TOF mass spectrometer. Molecular masses were accurately
measured and searched against known amino acid sequences of
human APP.
Purification of APMAP in E. coli and CHO
For the purification of recombinant human APMAP1-His6 in E.
coli, a pET21b vector encoding human APMAP1-His6 cDNA
was expressed in BL21(DE3) cells and induced with 1 mM
isopropyl-b-D-thiogalactopyranoside for 16 h at 248C at a
600 nm optical density of 0.8. For the purification of human
APMAP1-His6, harvested bacteria were lysed with 10 mM Tris
pH 7.4, 150 mM NaCl, 1% CHAPSO and complete protease
inhibitor cocktail (Roche) and passed three times through a high-
pressure homogenizer (Emulsiflex-C5; Avestin, Inc., Mannheim,
Germany) at a pressure greater than 1000 psi. The obtained lysate
was incubated for 1 h on ice and spun down at 5150g for 20 min at
48C, and the resulting supernatant was incubated for 30 min with
Ni-NTA agarose beads (Invitrogen) at room temperature. Bound
proteins were eluted five times in 10 mM Tris pH 7.4, 150 mM
NaCl and 1% CHAPSO containing 250 mM imidazole (pH 7.4)
and analyzed by Coomassie-stained SDS–PAGE.
For the purification of mammalian APMAP-Flag, a total of
2.64 × 109 CHO cells stably transfected with human APMAP1-
Flag were resuspended in MES buffer [50 mM MES pH 6.0,
150 mM NaCl, 5 mM MgCl2, 5 mM CaCl2 and protease inhibitor
cocktail (Roche)]. The cells were lysed by three passages in a
high-pressure homogenizer at a pressure greater than 1000 psi
and centrifuged at 3000g for 20 min. The supernatant was
further centrifuged at 100 000g for 1 h to pellet microsomes.
The pellet was resuspended by pipetting up and down 30 times
in bicarbonate buffer (0.1 M NaHCO3, pH 11.3) and incubated
for 20 min at 48C to remove non-integral proteins. The washed
microsomes were pelleted by centrifugation at 100 000g for
1 h. The supernatant was discarded, and the membranes were
solubilized in ice-cold 1% CHAPSO-HEPES lysis buffer
[50 mM HEPES, 150 mM NaCl, 5 mM MgCl2, 5 mM CaCl2, 1%
CHAPSO and protease inhibitor cocktail (Roche)] for 1 h at
48C. The lysate was centrifuged at 16 000g, saved and diluted
twice in HEPES buffer [50 mM HEPES, 150 mM NaCl, 5 mM
MgCl2, 5 mM CaCl2 and protease inhibitor cocktail (Roche)].
The lysate was further diluted six times in 0.1% digitonin-TBS
buffer (50 mM Tris–HCl pH 7.4, 150 mM NaCl) and bound to
M2 anti-Flag affinity resin (Sigma-Aldrich) overnight. Follow-
ing three washes in 0.1% digitonin-TBS buffer, the bound pro-
teins were eluted in 1.5 ml of 0.1% digitonin-TBS buffer
containing 0.2 mg/ml Flag peptides and used for the in vitro
g-secretase assays. In both protocols, the purity of human
APMAP1-His6 and APMAP1-Flag was confirmed by SDS–
PAGE using Coomassie staining.
g-Secretase activity assays
g-Secretase assays using recombinant human APMAP1 and
APP-C100-Flag were performed as previously reported (42–44).
Briefly, g-secretase purified from SS20 cells was solubilized in
0.2% (wt/vol) CHAPSO, 50 mM HEPES (pH 7.0), 150 mM
NaCl, 5 mM MgCl2 and 5 mM CaCl2 and incubated at 378C for
4 h with 1 mM substrate, 0.1% (wt/vol) phosphatidylcholine
and 0.025% (wt/vol) phosphatidylethanolamine. The resulting
products, AICD-Flag and Ab, were detected with Flag-specific
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M2 antibodies (Sigma-Aldrich) and Ab-specific 6E10 (Covance),
respectively.
Mice
Male and female WT and APP/PS1 transgenic mice (obtained
from Prof. M. Jucker, HIH, Tu¨bingen, Germany) were used.
APP/PS1 animals co-express the KM670/671NL Swedish muta-
tion of human APP and the L166P mutation of human PS1 under
the control of the Thy-1 promoter and show age-dependent accu-
mulation of parenchymal Ab plaques (45). Both WT and APP/
PS1 mice were generated on a C57BL/6J background. We con-
ducted all animal experiments in accordance with local and
federal directives for the care and use of laboratory animals.
Production and titration of AAV2/9 vectors
The production and titration of AAV vector particles pseudotyped
with a serotype 9 capsid has been described previously (46).
Briefly, the vectors were obtained by transient co-transfection of
293-AAV cells (Agilent, Santa Clara, CA, USA) with the
shuttle plasmid and a pDP9rs.gck helper plasmid, which
encodes the REP and CAP adeno-associated viral genes, as
well as genes that are essential to the adenoviral helper function
(plasmid kindly provided by Dr J. Kleinschmidt, Deutsches
Krebsforschungszentrum, Heidelberg, Germany). Viral vector
particles were purified from cell lysates by centrifugation on
an iodixanol gradient (OptiPrep, Axis-Shield, Oslo, Norway)
followed by anion exchange affinity chromatography on a
HiTrap Q-FF column (GE Healthcare Bio-Sciences AB,
Uppsala, Sweden). The suspension medium was replaced with
Dulbecco’s PBS (DPBS, Gibco), and the viral particles were
concentrated to a final volume of 100 ml using Centricon
Plus-20 filtration devices (regenerated cellulose, 100 000
MWCO, Millipore). Viral titers were determined by measuring
the number of viral genomes present in a given volume of the
vector suspension using real-time PCR. We used a primer and
probe set that anneals to the b-globin intron (fw: 5′-CGTGC
CAAGAGTGACGTAAG-3′; rv: 5′-TGGTGCAAAGAGGCA
TGATA-3′; TaqMan probe: 5′-FAM-TTGCCCTGAAAGAA
AGAGATTAGGGAA-BHQ-1-3′). The reactions were run in a
Corbett Rotor-Gene RG-3000 cycler (Qiagen Inc., Valencia,
CA, USA) using the following program: one cycle of 20 min at
958C for capsid denaturation followed by 40 cycles of 3 s at
958C and 10 s at 608C.
Injection of mice and Abmeasurements
The equivalent of 2.53 × 1010 and 1.10 × 1010 viral particles
were injected into 5-week-old WT and APP/PS1 mice, respect-
ively. Bilateral injection was performed at the following stereo-
taxic coordinates: (in mm, anterior, lateral, ventral to bregma)
22.1, 1.5, 1.7. After 4 weeks, the mice were euthanatized, and
the right hemisphere was homogenized in a buffer (1 ml
buffer/100 mg brain) containing 50 mM NaCl, 0.2% DEA and
complete protease inhibitor cocktail (Roche). After centrifuga-
tion at 200 000g for 35 min at 48C, soluble Ab peptide analysis
in WT and APP/PS1 brain lysates was performed using anti-
human/rat AbX-40 (Wako Chemicals, Richmond, VA, USA)
and anti-human Ab1-X (IBL International GmbH, Hamburg,
Germany), respectively, according to the manufacturer’s
instructions. Total proteins were subsequently extracted in 1%
NP40 and complete protease inhibitor cocktail (Roche) for
western blot analysis.
Statistical analyses
All data are presented as the mean+SD. Student’s t-test (two-
tailed) was applied for statistical analysis, and statistical signifi-
cance is shown asP , 0.05 (one asterisks),P, 0.01 (two aster-
isks) or P , 0.001 (three asterisks).
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